Cellyan Biotechnology Co., Ltd (HKPD)
NASDAQ: HKPD · Real-Time Price · USD
1.575
+0.050 (3.28%)
At close: Nov 10, 2026, 4:00 PM EST
1.570
-0.005 (-0.32%)
After-hours: Nov 10, 2026, 7:30 PM EST
Cellyan Biotechnology Revenue
In the fiscal year ending March 31, 2026, Cellyan Biotechnology had annual revenue of $13.43M, down -33.87%. Cellyan Biotechnology had revenue of $6.30M in the half year ending March 31, 2026, a decrease of -34.95%. That makes Cellyan Biotechnology the 35,998th largest company in the world by revenue and 4,722nd in the United States.
Revenue (ttm)
$13.43M
Revenue Growth
-33.87%
P/S Ratio
0.14
Revenue / Employee
$1,221,228
Employees
11
Market Cap
1.85M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.43M | -6.88M | -33.87% |
| Mar 31, 2025 | 20.31M | 3.63M | 21.72% |
| Mar 31, 2024 | 16.69M | 4.13M | 32.91% |
| Mar 31, 2023 | 12.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
HKPD News
- 18 days ago - Cellyan Biotechnology Co Ltd trading halted, news pending - TheFly
- 20 days ago - Cellyan Biotechnology to implement 1-for-20 reverse stock split - TheFly
- 20 days ago - Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split - GlobeNewsWire
- 3 months ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period - GlobeNewsWire
- 5 months ago - Cellyan Biotechnology files $200M mixed securities shelf - TheFly
- 7 months ago - Cellyan Biotechnology Co. files to sell 12.5M Class A ordinary shares for holder - TheFly
- 9 months ago - Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - GlobeNewsWire
- 10 months ago - Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders - GlobeNewsWire